Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update GlobeNewswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on LXRX
    Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
    9:31a ET March 13 '24 PR Newswire

    InvestorsObserver issues critical PriceWatch Alerts for LXRX, SAVA, CLSD, LTRN, and ATAI.

    https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg

    To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

    -- LXRX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=LXRX&prnumber=202403132

    -- SAVA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=SAVA&prnumber=202403132

    -- CLSD: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CLSD&prnumber=202403132

    -- LTRN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=LTRN&prnumber=202403132

    -- ATAI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ATAI&prnumber=202403132

    (Note: You may have to copy this link into your browser then press the [ENTER] key.)

    InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

    InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

    https://c212.net/c/img/favicon.png?sn=CG60336&sd=2024-03-13

    View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-lexicon-pharmaceuticals-cassava-sciences-clearside-biomedical-lantern-pharma-or-atai-life-sciences-302088039.html

    SOURCE InvestorsObserver

    https://rt.newswire.ca/rt.gif?NewsItemId=CG60336&Transmission_Id=202403130931PR_NEWS_USPR_____CG60336&DateId=20240313

    COMTEX_449186269/1005/2024-03-13T09:31:28

    Lonnel Coats Retires as Chief Executive Officer and Board Member of L...
    9:00a ET April 29 '24 GlobeNewswire
    Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results ...
    7:03a ET April 29 '24 GlobeNewswire
    Lexicon Pharmaceuticals to Host 2024 Investor Day
    8:01a ET April 18 '24 GlobeNewswire
    Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Vir...
    8:00a ET April 3 '24 GlobeNewswire
    Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Atta...
    9:21a ET March 25 '24 GlobeNewswire
    Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Scien...
    9:31a ET March 13 '24 PR Newswire
    New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In...
    8:02a ET March 12 '24 GlobeNewswire
    Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results...
    7:15a ET March 11 '24 GlobeNewswire
    Lexicon Announces Oversubscribed $250 Million Private Placement of Eq...
    7:05a ET March 11 '24 GlobeNewswire
    Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes F...
    7:00a ET March 11 '24 GlobeNewswire

    Market data provided by News provided by